Citizens Reiterates Buy Rating for Taysha Gene Therapies, Inc.
Citizens maintained its buy rating for Taysha Gene Therapies, setting a target price of $11, a 58.50% upside from the current price.
Key Points
- On June 23, 2026, Citizens reiterated its buy rating for Taysha Gene Therapies with a target price of $11.
- Citizens's $11 price target implies 58.50% upside from Taysha Gene Therapies, Inc.'s ($TSHA) current $6.94 share price.
- Shares of NasdaqGS:TSHA traded at $6.53 on Tuesday, with a market cap of $1.88 billion and a 52-week range of $2.25 to $7.30.
- B of A Securities, Needham, and Canaccord Genuity also maintain buy ratings, with targets ranging from $10 to $17.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Citizens reiterated its buy rating for Taysha Gene Therapies, Inc. (NasdaqGS:TSHA) on June 23, 2026, maintaining a price target of $11. Shares traded at $6.53 on Tuesday, reflecting the company's ongoing potential in the gene therapy space.
Analysts Set New Price Targets
On June 23, 2026, Citizens maintained its buy rating for Taysha Gene Therapies with a target of $11. B of A Securities also maintained a buy rating, setting a target of $10. Needham, on June 22, 2026, maintained its buy rating with a target price of $12. Canaccord Genuity earlier set a target of $17, reinforcing a positive outlook.
Taysha Gene Therapies, Inc. Stock Up 20.3%
Shares of NasdaqGS:TSHA traded at $6.53 on Tuesday. The company has a market cap of approximately $1.88 billion. Taysha Gene Therapies isn't currently profitable, so it has no meaningful P/E ratio. The stock has a 52-week low of $2.25 and a high of $7.30, with a 50-day moving average of $5.96 and a 200-day moving average of $4.88. The company shows strong liquidity with a current ratio of 14.04 and a quick ratio of 13.76.
$TSHA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Taysha Gene Therapies, Inc.
Several insiders made stock purchases on June 1, 2026. John Stalfort III, Alison Long, and Laura Sepp-Lorenzo each bought 42,671 shares, while Phillip Donenberg purchased 21,335 shares. These transactions were not part of a planned trading program.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc. is a biotechnology company focused on developing gene therapies for severe monogenic diseases of the central nervous system. Headquartered in Dallas, Texas, the company works on treatments for conditions like Rett syndrome and giant axonal neuropathy. Taysha collaborates with The University of Texas Southwestern Medical Center and is led by CEO Sean P. Nolan.
Bottom Line
Taysha Gene Therapies continues to attract analyst attention, with Citizens reiterating a buy rating and setting an $11 target. This follows a series of positive ratings from other firms, indicating confidence in the company's gene therapy pipeline. As with all 13F filings, it's important to remember that these ratings are based on past data and may not reflect current market conditions.
Get Taysha Gene Therapies, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TSHA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.